Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (81-90 of 175) with videos related to

Pageof 18
Sort By:
Translational Lung Cancer Research|August 14, 2023
<i>EGFR</i> exon 20 insertion mutations and <i>ERBB2</i> mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugatesDaniel Sentana-Lledo, Emmeline Academia, Hollis Viray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinibDaniel B Costa, Susumu Kobayashi, Shuchi S Pandya, et al.
JTO Clinical and Research Reports|March 30, 2023
<i>ALK</i> Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor-Responsive Lung Cancer Driver OncogeneZachary R Schoepflin, Emmeline Academia, Soravis A Osataphan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2017
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision TherapyDeepa Rangachari, Xiuning Le, Meghan Shea, et al.
Clinical Lung Cancer|March 20, 2026
Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With OsimertinibHyunwoo Kwon, Hollis Viray, Robert E Gaudet, et al.
Cancer Treatment Communications|January 24, 2017
Rapidly fatal advanced <i>EGFR</i>-mutated lung cancers and the need for rapid tumor genotyping in clinical practiceDeepa Rangachari, Lauren Drake, Mark S Huberman, et al.
JTO Clinical and Research Reports|January 17, 2024
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase InhibitorsIkei S Kobayashi, William Shaffer, Hollis Viray, et al.
Cell Death & Disease|August 9, 2024
Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancerMotohiro Izumi, Masanori Fujii, Ikei S Kobayashi, et al.
JAMA Oncology|July 9, 2016
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 TrialAmanda J Redig, Daniel B Costa, Myriam Taibi, et al.
Clinical Lung Cancer|July 7, 2016
EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-ReviewYuri Sheikine, Deepa Rangachari, Danielle C McDonald, et al.
Pageof 18

Showing results (81-90 of 175) with videos related to

Sort By:
Pageof 18
Translational Lung Cancer Research|August 14, 2023
<i>EGFR</i> exon 20 insertion mutations and <i>ERBB2</i> mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugatesDaniel Sentana-Lledo, Emmeline Academia, Hollis Viray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinibDaniel B Costa, Susumu Kobayashi, Shuchi S Pandya, et al.
JTO Clinical and Research Reports|March 30, 2023
<i>ALK</i> Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor-Responsive Lung Cancer Driver OncogeneZachary R Schoepflin, Emmeline Academia, Soravis A Osataphan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2017
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision TherapyDeepa Rangachari, Xiuning Le, Meghan Shea, et al.
Clinical Lung Cancer|March 20, 2026
Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With OsimertinibHyunwoo Kwon, Hollis Viray, Robert E Gaudet, et al.
Cancer Treatment Communications|January 24, 2017
Rapidly fatal advanced <i>EGFR</i>-mutated lung cancers and the need for rapid tumor genotyping in clinical practiceDeepa Rangachari, Lauren Drake, Mark S Huberman, et al.
JTO Clinical and Research Reports|January 17, 2024
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase InhibitorsIkei S Kobayashi, William Shaffer, Hollis Viray, et al.
Cell Death & Disease|August 9, 2024
Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancerMotohiro Izumi, Masanori Fujii, Ikei S Kobayashi, et al.
JAMA Oncology|July 9, 2016
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 TrialAmanda J Redig, Daniel B Costa, Myriam Taibi, et al.
Clinical Lung Cancer|July 7, 2016
EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-ReviewYuri Sheikine, Deepa Rangachari, Danielle C McDonald, et al.
Pageof 18